Roles of posttherapy 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy
- 293 Downloads
To assess the clinical roles of [18F]fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) performed 2-3 months after completion of concurrent chemoradiotherapy (CCRT), along with pretherapy characteristics, in patients with advanced squamous cell carcinoma of the uterine cervix enrolled in a prospective randomized clinical trial.
Posttherapy PET/CT in patients with advanced FIGO stage or positive pelvic or para-aortic lymph node (PALN) defined on pretherapy PET/CT was classified as positive, equivocal, or negative. Overall survival (OS) rates between patients with different PET/CT results are compared. Pretherapy characteristics are examined for association with posttherapy PET/CT results and for prognostic significance in patients with equivocal or negative PET/CT.
PET/CT scans (n = 55) were positive, equivocal and negative in 9, 13 and 33 patients, respectively. All patients with positive scans were confirmed to have residual or metastatic disease and died despite salvage therapies. There is a significant OS difference between patients with positive and equivocal scans (P < .001) but not between patients with equivocal and negative scans (P = .411). Positive pretherapy PALN is associated with positive posttherapy PET/CT (P = .033) and predicts a poorer survival in patients with equivocal or negative posttherapy PET/CT (P < .001).
Positive PET/CT 2-3 months posttherapy implies treatment failure and novel therapy is necessary to improve outcomes for such patients. A more intense posttherapy surveillance may be warranted in patients with positive pretherapy PALN.
Keywords18F-FDG PET/CT Advanced cervical cancer Concurrent chemoradiotherapy Posttherapy surveillance Prognosis
This study was funded by Chang Gung Memorial Hospital, Linkou (CMRPG381141 and CMRPG381142).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
We obtained informed consents from all individual participants included in the study.
- 1.Jaime P, Silvia F, Lynette D, Eduardo LP. Cancers of the female reproductive organs. In: Bernard WS, Christopher PW, editors. World Cancer Report 2014. Lyon: World Health Organization; 2014. p. 465-481.Google Scholar
- 2.Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.CrossRefPubMedCentralGoogle Scholar
- 4.Siva S, Deb S, Young RJ, Hicks RJ, Callahan J, Bressel M, et al. 18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. Eur J Nucl Med Mol Imaging. 2015;42:1825–32.CrossRefPubMedGoogle Scholar
- 5.Scarsbrook A, Vaidyanathan S, Chowdhury F, Swift S, Cooper R, Patel C. Efficacy of qualitative response asessment interpretation criteria at 18F-FDG PET-CT for predcting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2017;44:581–8.CrossRefPubMedGoogle Scholar
- 8.Wang CC, Chou HH, Yang LY, Lin H, Liou WS, Tseng CW, et al. A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: an Asian gynecologic oncology group study. Gynecol Oncol. 2015;137:462–7.CrossRefPubMedGoogle Scholar
- 9.Liu FY, Lai CH, Yang LY, Wang CC, Lin G, Chang CJ, et al. Utility of 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial. Eur J Nucl Med Mol Imaging. 2016;43:1812–23.CrossRefPubMedGoogle Scholar
- 10.Su TP, Lin G, Huang YT, Liu FY, Wang CC, Angel C, et al. Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging. Published online first: Nov 20, 2017. https://doi.org/10.1007/S00259-017-3884-0.
- 22.Choi HJ, Ju W, Myung SK, Kim Y. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci. 2010;101:1471–9.CrossRefPubMedGoogle Scholar